RT期刊文章SR电子T1最小平均临床重要差异,最好的,最糟糕的电流强度和不愉快的慢性呼吸困难摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP 1902202 10.1183/13993003.02202 -2019签证官56 2 A1埃克斯特龙,马格努斯A1约翰逊,188bet官网地址Miriam J. A1 Huang, Chao A1 Currow, David C. YR 2020 UL //www.qdcxjkg.com/content/56/2/1902202.abstract AB背景慢性呼吸困难具有毁灭性的后果。最小临床重要差异(MCID)的电流强度被估计为9毫米在100毫米视觉模拟评分(VAS)。我们的目标是确定MCIDs的常用维度和回忆期:当前不愉快和当前、平均、最佳和最差强度的过去24小时慢性呼吸困难。这是一项对严重疾病所致慢性呼吸困难患者使用吗啡与安慰剂进行为期7天的随机对照试验的二次分析。每天晚上使用日记在100毫米VAS上自我报告呼吸评分。使用基于锚点和基于分布的方法估计每个分数的改善MCID。283名参与者(平均年龄74.2岁;男性63%;58%的慢性阻塞性肺病;纳入87.0%修改后的mMRC (Medical Research Council, mMRC)评分3-4)。基于锚的MCIDs的呼吸评分范围为−13.9 mm至−9.5 mm。 The MCIDs were similar when using different anchors and across all participants, and participants with more severe breathlessness (mMRC 3–4). Distribution-based effect sizes were classed as small (−4.7−6.3 mm), moderate (−9.4−12.5 mm) and large (−15.0−20.0 mm) effect. Sample sizes for trials using the different scores were proposed. MCIDs of absolute change were more stable than using relative change from baseline.Conclusion An improvement of ∼10 mm on a 100-mm VAS is likely to be clinically meaningful across commonly used measures of chronic breathlessness (current intensity, unpleasantness, and average, best and worst intensity over the past 24 h) to evaluate clinical benefit and effects in therapeutic trials.This cohort study determined clinically important differences for current intensity and unpleasantness and the average, best and worst intensity of the past 24 h of chronic breathlessness, which is important for the design of therapeutic trials https://bit.ly/3amslss